Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study

David Lau, Eleftheria Kalaitzaki, David N Church, Hardev Pandha, Ian Tomlinson, Nicola Annels, Marco Gerlinger, Francesco Sclafani, Gillian Smith, Ruwaida Begum, Richard Crux, Angela Gillbanks, Sarah Wordsworth, Ian Chau, Naureen Starling, David Cunningham, Tony Dhillon

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)e000638
JournalESMO Open
Volume5
Issue number1
DOIs
Publication statusPublished - 5 Feb 2020

Cite this